In that respect, activating mutations in the epidermal growth factor receptor (EGFR) represent one of the best known and most commonly found oncogenic drivers in NSCLC, which can be inhibited by targeted therapies (Lung Cancer Group Cologne 2018; Nguyen-Ngoc et al. 2017). The gene discussed is EGFR; the disease is lung carcinoma.